Psychedelic Bulletin #136: MindMed Collaborators Share Topline LSD for MDD Results; Oregon Issues Psilocybin Licences; UK Parliament to Discuss Psilocybin Rescheduling

This week, we’re providing a look ‘under the hood’ at how we track psychedelic drug policy reform across the United States. The below updates are more granular than those in our Psychedelic Legalization & Decriminalization Tracker, which is produced with the support of experts at Calyx Law and Emerge Law Group.These updates reflect the period April 10 – 28, 2023 SB 303 – OregonRelating to Psilocybin Services; Prescribing and Effective DateIntroduced: January 6, 2023Latest Action Date: April 20, 2023Latest Action: Referred to Behavioural Health and Health CareNext Action: Work Session Schedule for May 8, 2023On April 20, 2023, SB 303 was referred by the House to the Behavioural Health and Health Care committee. The bill will now be reviewed and the committee will hold a public hearing and work session which are scheduled for May 3rd and May 8th respectively. If passed into law, SB 303 would require psilocybin service centres and facilitators to collect and report data on client details, adverse events, and other related information. SB 23-290 – ColoradoNatural Medicine Regulation and LegalizationIntroduced: April 18, 2023Latest Action Date: April 27, 2023Latest Action: Referred to AppropriationsNext Action: To be assigned to committee by HouseOn April 18, 2023, SB 23-290 was introduced into the Colorado Senate. The bill, which passed through the Senate within a week, was introduced in the House on April 25, 2023. The amended bill has recently been referred to Appropriations by the House Committee on Finance and if referred favourably, will advance through subsequent readings in the House before it is ultimately voted on. If passed into law, SB 23-290 would establish the regulatory framework for the implementation of Colorado’s Natural Medicine Health Act which was passed in November 2022. HB 1340 – HawaiiRelating to Mental HealthIntroduced: January 25, 2023Latest Action Date: April 27, 2023Latest Action: Conference Committee MeetingNext Action: Conference Committee Meeting to Reconvene on April 28, 2023 On April 11, 2023, Hawaii’s HB 1340 was passed by the Senate with a total of 24 votes for and none against. However, on April 13, after the amended bill was returned from the Senate, the House issued a notice regarding its disagreements with Senate amendments. HB 1340 has been subsequently referred to a conference committee where areas of disagreement will be considered. If signed into law, HB 1340 would establish the “Beneficial Treatments Advisory Council” to, amongst other things, “develop a long-term strategic plan to ensure the availability of therapeutic psilocybin, psilocybin-based products, and methylenedioxymethamphetamine that are safe, accessible, and affordable…” SB 58 – CaliforniaControlled Substances: Decriminalization of Certain Hallucinogenic SubstancesIntroduced: December 16, 2022Latest Action Date: April 25, 2023Latest Action: Senate hearing set for May 1, 2023Next Action: Senate hearingOn April 25, 2023, after being re-referred to the Committee on Appropriations, a hearing date was set for California’s SB 58. Following the hearing, the committee must vote on passing or defeating the bill before it can be advanced further in the legislative process.  If enacted, SB 58 would, amongst other things, “make lawful the possession, preparation, obtaining, transfer, as specified, or transportation of, specified quantities of psilocybin, psilocyn, dimethyltryptamine (DMT) , ibogaine, and mescaline, for personal use or facilitated or supported use, as defined, by and with persons 21 years of age or older.” SB 242 – NevadaRequires the Department of Health and Human Services to establish the Psychedelic Medicines Working GroupIntroduced: March 9, 2023Latest Action Date: April 24, 2023Latest Action: Re-referred to Committee on FinanceNext Action: Awaiting committee recommendation/determination On April 21, 2023, the Committee on Health and Human Services recommended SB 242 pass as amended. However, the bill was subsequently re-referred to the Committed on Finance for further consideration. So long as the committee does not vote to postpone the consideration of SB 242, the bill will progress further through the legislative process. If enacted, the bill would require Nevada’s Department of Health and Human Services to “establish the Psychedelic Medicines Working Group to study certain issues relating to the therapeutic use of entheogens”. SB 5263 – WashingtonConcerning Access to Psilocybin Services by Individuals 21 Years of Age and OlderIntroduced: January 11, 2023Latest Action Date: April 20, 2023Latest Action: Delivered to GovernorNext Action: Awaiting final action/inaction from Governor On April 20, 2023, Washington’s SB 5263 was delivered to the state’s governor after being accepted by both the House and Senate. The bill will now foreseeably be signed into law by the governor. SB 5263, when introduced, sought to regulate psilocybin services for individuals over the age of 21 in the state. However, SB 5263 underwent some significant changes after a Senate committee approved a substitute bill which narrowed the bill’s scope in late February 2023. Consequently, SB 5263 is now focused on the establishment of “an advisory board, interagency work group, and task force to provide advice and recommendations” for regulating access to psilocybin services. HB 727 – North CarolinaBreakthrough Therapies Research/Advisory ActIntroduced: April 18, 2023Latest Action Date: April 19, 2023Latest Action: Referred to Committee on HealthNext Action: Awaiting committee recommendation/determination On April 18, 2023, HB 727 was introduced in North Carolina. After passing its first reading on April 19th, the bill was referred to the House Committee on Health. If referred favourably, the bill will pass through the committees on Appropriations and subsequently Rules, Calendar, and Operations before proceeding through the nearly steps early in the legislative process. If eventually signed into law, HB 727 would establish a Breakthrough Therapies Research Grant Fund that would provide two $2.5m grants to North Carolina research projects investigating the use of MDMA or Psilocybin to treat certain psychiatric indications in qualifying patient populations. HB 6734 – ConnecticutAn Act Concerning the Decriminalization of Possession of Small Amounts of PsilocybinIntroduced: February 22, 2023Latest Action Date: April 17, 2023Latest Action: Bill assigned House Calendar NumberNext Action: To be debated and voted on in the HouseOn April 17, 2023, after passing out of committee, HB 6734 was given a favourable report and was consequently tabled for the Calendar in the House. HB 6734 will now be debated and amendments to the bill can be proposed before a final House vote occurs. Should HB 6734 eventually be signed into law, criminal penalties for possession of up to one-half ounce of psilocybin would be eliminated. HF 240 – IowaA Bill for An Act Removing Psilocybin and Psilocyn from the List of Substances Classified As Schedule I Controlled Substances Under Iowa’s Uniform Controlled Substances ActIntroduced: 8/2/2023 February 2, 2023Latest Action Date: April 11, 2023Latest Action: Subcommittee recommends passageNext Action: Awaiting committee recommendation/determination On April 11, 2023, an Iowa subcommittee, through a vote, recommended the passage of HF 240. The full committee will now discuss the subcommittee’s conclusions and present its recommendations to the House. If enacted, the bill would see psilocybin and psilocyn removed from Iowa’s list of schedule I controlled substances under its uniform controlled substances act.



Source link